Ventfort
A Khavinson bioregulator made from bovine vascular tissue, sold in Russia for vascular aging. No published sequence or PubMed record names it.
A peptide bioregulator preparation from bovine vascular tissue in the Khavinson series, sold in Russia and CIS states as a supplement for age-related vascular decline. No paper indexed on PubMed names Ventfort and we found no published sequence for it. An earlier version of this entry gave it the KEDG tetrapeptide; the papers that name KEDG assign it to testagen or describe it as pituitary-derived, so that sequence has been removed.
Mechanism of action
Proposed to support endothelial aging and vascular homeostasis via the Khavinson-framework tissue-specific gene-expression modulation hypothesis. Not independently validated in Western literature.
Primary uses
- Vascular / endothelial aging support (Russian nutraceutical positioning)
- Microcirculatory support (anecdotal)
Typical dosing
The amounts in circulation come from the maker's directions, not a controlled study, so no amount is printed here.
Regulatory status
Not FDA- or EMA-approved. Sold in Russia and CIS states as a nutraceutical; not a registered medicine in any Western jurisdiction.
Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
No paper indexed on PubMed names Ventfort and no sequence for it has been published that we could find. This section records what was checked, including why the sequence this entry used to give was removed.
Identity, computed
| Sequence | Not established |
Until October 4, 2026 this entry gave Ventfort the tetrapeptide Lys-Glu-Asp-Gly (KEDG), citing a 2011 review we could not find. Every indexed paper that names KEDG assigns it elsewhere: a 2025 paper in Molecules calls it testagen, and Russian papers from 2008 to 2013 describe it as a synthetic peptide modelled on pituitary extract. So the sequence, formula and mass were removed; the KEDG papers are on the testagen entry.
Regulatory status, read October 4, 2026
Drugs@FDA: 0 records for “ventfort”. EMA medicines list: 0 records for “ventfort”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.
What the maker or sellers claim
Claim, from Russian sellers: Ventfort, made from bovine blood-vessel tissue, supports aging vessels, the endothelium and microcirculation. No indexed study tests Ventfort for any of these.
About vascular peptide preparations, not this product
The calf vessel-wall polypeptide complex that does appear on PubMed is called Slavinorm (also Vasolin) in its papers. A 2019 Russian review describes animal studies in models of atherosclerosis and other age-related disease (Khavinson et al., 2019), and in aged rats a course of Slavinorm increased the density of the brain-surface microvessel network about 2.5-fold (2016). Nothing we found says Slavinorm and Ventfort are the same product, so those results are not evidence for Ventfort.
The synthetic vascular peptide in the same series is vesugen (Lys-Glu-Asp), which has its own entry.
What we looked for and did not find
No study naming Ventfort in any species, no published sequence, no pharmacokinetic data, no registry record and no dose from a controlled study.
| Source | Query | Results, October 4, 2026 | What it was |
|---|---|---|---|
| PubMed | ventfort | 0 | |
| PubMed | Lys-Glu-Asp-Gly | 10 | KEDG papers: pituitary-modelled peptide and testagen |
| PubMed | Khavinson vessels peptide | 20 | Slavinorm and vesugen papers |
| NLM MeSH | ventfort | 0 | no record |
| ClinicalTrials.gov | ventfort | 0 | |
| Drugs@FDA (openFDA) | ventfort | 0 | |
| EMA medicines list | ventfort | 0 |
References
- [review] Khavinson VK, et al. "Short peptides and tissue-specific gene expression: the Khavinson bioregulator framework." Bull Exp Biol Med, 2011;151:1-8.
- [review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149. PMID: 19830585.
- [pubmed] Sokolova IB, et al. "Effects of Vascular Peptide Bioregulator on the Density of Microvascular Network in the Brain Cortex of Aged Rats." Bull Exp Biol Med, 2016;161(2):300-3. PMID: 27383168.
- [pubmed] Kuznik BI, et al. "[Polypeptide vessel complex and its role in physiology function regulation in aging pathology.]." Adv Gerontol, 2019;32(1-2):174-179. PMID: 31228385.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.